生物医学数据库参考答案

生物医学数据库实习题实习目的：1.请先熟悉PUBMED的检索界面、检索功能及检索方法。2.针对一个检索题目，掌握检索步骤与检索策略(特别是检索词与检索式)。3.完成实习报告实习要求：1、请同学们独立完成，把答案直接粘贴在问题下面。 2、写出检索入口、检索词、检索式及检索结果的篇数。PubMed1.检索我校(注意我校有更名的情况)近5年来被PubMed收录的文献。步骤：1.进入pubmed 2. 检索式：Fujian College of Traditional Chinese Medicinead OR Fujian University of Traditional Chinese Medicinead 3. filters出版时间：publication dates=5 years4.检索结果：229篇。2.请查找近5年发表的有关伊曲康唑（Itraconazole）语种为英文随机对照实验有免费全文的文献，任选两篇以题录（summary）的格式保存。（1）进入Pubmed （2）检索词：Itraconazolefilters: languages=English Text availabilityfree full text available publication dates=5 yearsType of Article= Randomized Controlled Trial （3）检索结果12篇1: Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R,Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013 May;8(5):619-23. doi: 10.1097/JTO.0b013e31828c3950. PubMed PMID: 23546045; PubMed Central PMCID: PMC3636564.2: Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013;18(2):163-73. doi: 10.1634/theoncologist.2012-314. Epub 2013 Jan 22. PubMed PMID: 23340005; PubMed Central PMCID: PMC3579600.3. 亚特那唑（sporanox）是否是主题词，如果不是，它的主题词是什么？它的树形结构是什么？检索有关亚特那唑药学或药代动力学的研究并且为主要主题词文献，并任选两篇以abstract 的格式保存。 步骤：（1）进入Pubmed的Mesh database检索界面 sporanox不是主题词，它的主题词为：Itraconazole树形结构：All MeSH CategoriesChemicals and Drugs CategoryHeterocyclic CompoundsHeterocyclic Compounds, 1-RingAzolesTriazolesItraconazoleAll MeSH CategoriesChemicals and Drugs CategoryHeterocyclic CompoundsHeterocyclic Compounds, 1-RingPiperazinesItraconazole组配副主题词：pharmacokinetics与pharmacology，并且限定：Restrict to MeSH Major Topic.检索表达式：( Itraconazole/ pharmacokinetics Majr OR Itraconazole/pharmacologyMajr )检索结果：989篇。J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3.cited by:Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.Kim DJ1, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY.Author informationAbstractPURPOSE:Itraconazole, a US Food and Drug Administration-approved antifungal drug, inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) tumorigenesis, and reduces BCC growth in mice. We assessed the effect of itraconazole on the HH pathway and on tumor size in human BCC tumors.PATIENTS AND METHODS:Patients with one BCC tumor 4 mm in diameter were enrolled onto two cohorts to receive oral itraconazole 200 mg twice per day for 1 month (cohort A) or 100 mg twice per day for an average of 2.3 months (cohort B). The primary end point was change in biomarkers: Ki67 tumor proliferation and HH activity (GLI1 mRNA). Secondary end points included change in tumor size in a subset of patients with multiple tumors.RESULTS:A total of 29 patients were enrolled, of whom 19 were treated with itraconazole. Itraconazole treatment was associated with two adverse events (grade 2 fatigue and grade 4 congestive heart failure). Itraconazole reduced cell proliferation by 45% (P = .04), HH pathway activity by 65% (P = .03), and reduced tumor area by 24% (95% CI, 18.2% to 30.0%). Of eight patients with multiple nonbiopsied tumors, four achieved partial response, and four had stable disease. Tumors from untreated control patients and from those previously treated with vismodegib showed no significant changes in proliferation or tumor size.CONCLUSION:Itraconazole has anti-BCC activity in humans. These results provide the basis for larger trials of longer duration to measure the clinical efficacy of itraconazole, especially relative to other HH pathway inhibitors.Comment in Discovery and exploitation of novel targets by approved drugs. J Clin Oncol. 2014PMID: 24493717 PubMed - indexed for MEDLINE 2.Poult Sci. 2014 Jan;93(1):12-5. doi: 10.3382/ps.2013-03541.cited by:Mutations in the Cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus isolated from avian farms in France and China.Wang DY1, Gricourt M, Arn P, Thierry S, Seguin D, Chermette R, Huang WY, Dannaoui E, Botterel F, Guillot J.Author informationAbstractAzole resistance in the fungal pathogen Aspergillus fumigatus is an emerging problem and may develop during azole therapy in humans and animals or exposure to azole fungicides in the environment. To assess the potential risk of azole-resistance emergence in avian farms where azole compounds are used for the control of avian mycoses, we conducted a drug susceptibility study including A. fumigatus isolates from birds and avian farms in France and Southern China. A total number of 175 isolates were analyzed: 57 isolates were collected in France in avian farms where chemoprophylaxis with parconazole was performed; 51 isolates were collected in southern China in avian farms where no chemoprophylaxis was performed; and 67 additional isolates came from the collection of a mycology laboratory. No resistant isolate was detected, and the distribution of minimum inhibitory concentrations was similar for isolates collected in farms with or without azole chemoprophylaxis. For 61 randomly selected isolates, the full coding sequence of the Cyp51A gene was determined to detect mutations. Nine amino acid alterations were found in the target enzyme, 3 of which were new.KEYWORDS:Aspergillus fumigatus, China, France, azole drug, susceptibilityPMID: 24570417 PubMed - indexed for MEDLINE4.请问pubmed一共收录了中国中西医结合杂志（中文版、英文版）多少篇文献；其中作者来自福建省的有多少篇，任选两篇以abstract 的格式保存。1.进入pubmed ,采用字段限定检索方式2.方法一：”zhongguo zhong xi yi jie he za zhi”TA OR “Chinese Journal of Integrative Medicine”TA方法二：1003-5370 OR 1672-04153.检索结果：6447篇3.福建省： (”zhongguo zhong xi yi jie he za zhi”TA OR “Chinese Journal of Integrative Medicine”TA) AND FujianAD4.检索结果：143篇。Chin J Integr Med. 2014 Feb;20(2):123-9. doi: 10.1007/s11655-013-1581-9. Epub 2014 Mar 6.Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway.Zhao JY1, Chen ZH, Lin W, Zhong XY, Chen XZ, Peng J, Hong ZF.AbstractOBJECTIVE:To evaluate the effect of Bear Bile Powder(, BBP) on the growth and apoptosis of HepG2 human hepatocellular carcinoma cells, and investigate the possible molecular mechanisms mediating its anti-cancer activity.METHODS:HepG2 cells were treated with 0.4-1.0 mg/mL of BBP for 24, 48 and 72 h. The viability of HePG2 cells was determined by MTT assay. Cellular morphology was observed via phase-contrast microscopy. Fluorescence-activated cell sorting analysis with Annexin-V/propidium idodide and 5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-benzimidazol-carbocyanine iodide (JC-1) staining was performed to determine cell apoptosis and the loss of mitochondrial membrane potential, respectively. Activation of caspase-9 and -3 was evaluated by a colorimetric assay.RESULTS:The treatment with 0.4-1 mg/mL of BBP for 24, 48, or 72 h respectively reduced cell viability significantly by 7%-60%, 20%-90% or 25%-98%, compared with the untreated control cells (P0.01). In addition, BBP treatment induced morphological changes in HepG2 cells. Furthermore, after treated with 0, 0.4, 0.6, 0.8 and 1.0 mg/mL of BBP, apoptosis cells (including early and late apoptotic cells) were 18.0%1.3%, 34.9%2.2%, 33.9%2.8%, 37.4%2.8% and 46.0%2.5%, respectively (P0.05); and the percentage of cells with reduced JC-1 red fluorescence were 6.6%0.8%, 8.5%0.8%, 13.5%1.6%, 17.6%2.3% and 46.7%3.6%, respectively (P0.01). Finally, BBP treatment significantly and dose-dependently induced activation of both caspase-9 and caspase-3 in HepG2 cells (P0.05).CONCLUSIONS:BBP could inhibit the growth of HepG2 hepatocellular cancer cells through mitochondrion-mediated apoptosis, which may, in part, explain its anti-cancer activity. BBP may be a potential novel therapeutic agent for the treatment of hepatocellular carcinoma.PMID: 24619237 PubMed - in process 2.Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Jan;34(1):81-6.In vitro culture and identification of IL-1beta induced degeneration of cartilage cells in New Zealand white rabbits knee joint.Article in ChineseYan H, Su YX, Lin XY.AbstractOBJECTIVE:To explore and identify the method for IL-1beta induced New Zealand rabbit knee chondrocyte degeneration, thus providing experimental bases for Chinese medical research on osteoarthritis from in vitro cultured chondrocytes.METHODS:Under aseptic conditions, bilateral knee joint cartilage was collected from 4-week old New Zealand rabbits. Chondrocytes were separated by type II collagenase digestion and mechanical blowing method. They were randomly divided into two groups when passaged to the 2nd generation, the normal control group (group Z) and the IL-1beta induced model group (group M). No intervention was given to those in group Z. 10% FBS culture media containing 10 ng/mL IL-1beta was added to group M. All cells were passage